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With the current national commitment to cancer research, new and challenging
areas ofinvestigation are being planned. Hopefully, this inevitably expanding search
into the nature and treatment of malignant tumors will include a continued exami-
nation of current chemotherapeutic agents. These standard tumoricidal drugs have
proved to be effective in the therapy of numerous cancers despite an incomplete
understanding of their mode of action in many cases (1-4). A further unraveling of
the pharmacologic basis of these drugs should undoubtedly lead to a greater thera-
peutic effect, perhaps producing longer remissions and increased cures.
A recent example of how continued basic research on available antineoplastic
agents may reveal findings pertinent to clinical chemotherapy concerns metho-
trexate, a drug frequently employed in the treatment of cancer (1-5, 66). Tradi-
tionally, the mode of action of this drug has assumed to be as an analog of the vi-
tamin folic acid. In humans, folic acid is biologically inactive, requiring reduction by
an enzyme termed "dihydrofolate reductase" to dehydrofolate, and then to tet-
rahydrofolate. This latter compound accepts 1-carbon fragments from various
sources to produce the folate coenzymes. These compounds act as 1-carbon donors
in numerous biochemical reactions, including the synthesis of the B-carbon of
serines, the formation of the C-2 and C-8 units of the purine skeleton, and the
methylation of thymidylic acid (5-7, 10, 12, 13, 15, 17, 18, 66). Methotrexate acts,
then, by irreversibly binding to and inhibiting the enzyme dihydrofolate reductase
thereby interfering with the maintenance of intracellular pools of reduced folates,
particularly N5''0-methylenetetrahydrofolate (1, 5, 11-13, 66). This latter compound
is necessary for the conversion of deoxyuridylate to thymidylate which is an
essential component of DNA. As is evident, methotrexate, as well as other antifo-
late agents, essentially act by inhibiting DNA synthesis (1-9, 11-12, 14-20, 27-40,
54, 66).
For many years it was accepted that the biological effects of methotrexate were
due entirely to its inhibition ofthe enzyme dihydrofolate reductase. Since free or un-
bound intracellular methotrexate accumulates only after all the dihydrofolate
reductase binding sites are saturated, little biological activity or significance has
been ascribed to this free intracellular drug component. However, evidence has been
accumulating that methotrexate may have a second site ofaction ofequal or greater
importance than the inhibition ofdihydrofolate reductase and furthermore, that it is
the unbound intracellular drug that is involved with this alternative site. Roberts et
al. (35-37), several years ago, demonstrated a lack of correlation between the in-
hibition ofdihydrofolate reductase activity in human leukemia cells and the response
ofleukemia patients to methotrexate therapy. On the basis oftheir studies, although
without substantiating data, this group theorized that free intracellular metho-
trexate as well as that bound to dihydrofolate reductase may have a significant role
in the cytocidal effect produced by this agent. Further evidence suggestive of an ad-
ditional site ofmethotrexate activity was next provided by Borsa and Whitmore (15,
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17, 18). Utilizing a subline of Earle's L-cells under conditions which permitted the
examination of methotrexate induced inhibition ofthymidylate and purine synthesis,
Borsa and Whitmore believed that their data are consistent with the interpretation
that methotrexate has sites of action in addition to its inhibition of dihydrofolate
reductase. In subsequent studies, these investigators (18) demonstrated that one
possible alternative siteofintracellular methotrexate action was thedirect inhibition
of the enzyme thymidylate synthetase which is necessary for DNA synthesis.
Recently, Goldman (7, 16)has confirmed and extended thesefindings. He found that
when murine L-cells were loaded with intracellular methotrexate sufficient to bind
all of the dihydrofolate reductase without accumulating in the free state, there was
only a small decrease in the rateofDNA synthesis. Only with the addition offurther
methotrexate, resulting in the accumulation of free intracellular drug in excess of
the level of dihydrofolate reductase, was Goldman able to produce complete sup-
pression of DNA synthesis within his experimental system. He also demonstrated
that methotrexate is capable ofbinding to and inhibiting thymidylate synthetase, al-
though as Goldman indicated, this does not necessarily mean this is an alternate site
of methotrexate activity in vivo. In a recent report concerned with this problem, Si-
rotnak and his co-workers (55) concluded that the target enzyme dihydrofolate
reductase is the primary site of methotrexate activity at least in L1210 murine
leukemia cells. They ascribed the requirement for high levels of free intracellular
methotrexate (i.e., in excess of that required to completely inhibit dihydrofolate
reductase) described by other investigators (7, 16-18, 35-37) to an aberrant meta-
bolic state under the in vitro conditions utilized in these studies which does not allow
normal proliferative activity (55). To achieve 100% inhibition of DNA synthesis in
vivo according to Sirotnak et al. (55), levels of methotrexate only slightly above the
content ofdihydrofolate reductase are necessary to inhibit that fraction of enzyme
which for unknown reasons is not bound tightly to the drug and, therefore, capable
of continuing DNA synthesis. When the intracellular methotrexate concentration
decreases below this level, enough enzyme would theoretically be freed to reinstitute
DNA synthesis. Thus, Sirotnak and Donsbach believe thathigh drug concentrations
are not required for attaining maximal inhibition of DNA synthesis, but rather to
sustain this inhibition with decreasing plasmadrug levels.
While recognizing the controversy surrounding its acceptance, this multiple-site
hypothesis of methotrexate action does prcvide a heuristic model that allows for in-
creased speculation as to the nature ofobservable clinical phenomena. For example,
the therapeutic value of high-dose methotrexate treatment followed by citrovorum
rescuehaslong been recognized (23-28, 56-58). The basis for this combination drug-
rescue protocol is the observation that when citrovorum administration is delayed
for several hours after methotrexate therapy, the antineoplastic effect ofthe drug is
retained while host tissue toxicity is reduced (23-28, 50, 56-58). In the past, the ac-
cepted biochemical rationale for this treatment modality related the addition of
citrovorum factor or N5-formyltetrahydrofolate to a circumvention of the metho-
trexate-induced block of thymidylate synthesis with a consequent reinitiation of
DNA synthesis. Why this compound selectively rescues normal tissue with little
decrease in therapeutic effect has remained problematical. However, the multiple-
site theory of methotrexate activity coupled with recent, although still uncor-
roborated, reports demonstrating a greater persistence of this drug in malignant
cells as compared to sensitive normal host proliferative tissue (55, 59) provides a
speculative basis for the effectiveness ofhigh-dose methotrexate-citrovorum rescue
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protocols (65). With high doses of methotrexate, one can hypothesize that satu-
ration of the dihydrofolate reductase binding sites with a subsequent accumulation
of high intracellular levels of free drug might occur in most cells. As suggested by
the work ofSirotnak and Donsbach (55, 59), the intracellular drug concentration in
normal cells may return to the level of the enzyme dihydrofolate reductase while
that in the tumor cells remains elevated for alonger period. Should this hypothetical
situation exist, citrovorum factor administered during this time would allow normal
cells to recover proliferatively by bypassing the methotrexate-induced block of the
enzyme dihydrofolate reductase. DNA synthesis in the tumor cells, on the other
hand, would still be prevented despite the presence of citrovorum factor by free in-
tracellular methotrexate inhibiting alternative sites involved in DNA synthesis (65).
While this alternative site may be thymidylate synthetase as suggested by the studies
of Borsa et al. (15, 17, 18) and others (7, 16), other possibilities exist. For instance,
Hryniuk has proposed that cells exposed to methotrexate may die a purineless death
as well as a thymineless death. Thus, a continued block in purine synthesis produced
by high intracellular drug levels in malignant as compared to normal cells may be
the alternative and/or additional site ofmethotrexate activity. An interesting thera-
peutic aspect ofthis multiple site hypothesis of(methotrexate) activity is the expec-
tation that prolonged high intracellular concentrations of methotrexate may prove
to have a greater antitumor effect, particularly ifthis elevation is limited to the ma-
lignant cells. In this regard, Zager et al. (67) and Fyfe and Goldman (16,66) have
demonstrated that methotrexate uptake is augmented by vincristine as a conse-
quence ofinhibition ofefflux from the cell or by enhanced binding ofmethotrexate to
alternative sites. While its in vivo effect has been questioned (68), vincristine may
enhance methotrexate activity and certainly should be investigated further. Despite
its speculative basis, the above hypothesis indicates the possible significance of the
multiple site ofaction theory in explaining experimentally and clinically derived data
as well as possible future therapeutic manipulations deserving of further investi-
gation.
Irrespective ofits specific site ofaction, thereis ampleevidence that methotrexate
produces its cytoxic effects by inhibiting DNA synthesis (1-8, 16-20, 22, 29-34, 38-
41, 45-48, 55). As such, another important aspect of this drug, only recently ap-
preciated, is its effects upon groups of normal and malignant cells actively tra-
versing the cell cycle (45-49, 51-53, 63, 64). The cell cycle is defined as the interval
between the midpoint of mitosis in the parent cell and the midpoint of the subse-
quent mitosis in one or both daughter cells (60). While theduration ofthe cycle may
vary with different cell types, the following four phases have been uniformly
identified in most systems: (1) G1, the period between completion ofmitosis and the
onset of DNA synthesis; (2) S, the DNA replication period; (3) G2, the time be-
tween completion of DNA synthesis and the onset of mitosis, (4) M or mitosis, the
period involving prophase, metaphase, anaphase, and telophase during which the
chromosomes segregate, and are equally distributed to the dividing cells (60). Ernst
and Kilman (45, 46) have demonstrated that methotrexate arrests human leukemia
cells in the S phase for a period of time corresponding to the length of DNA syn-
thesis. This cytocidal effect was restricted to those cells that were in the S phase
during methotrexate administration. Cells in G1, M, G2 were not directly influenced
by the drug. This cell cycle phase specificity ofmethotrexate has been confirmed by
other investigators (47, 50).
Based upon these observations, treatment schedules have been proposed in an at-
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tempt to utilize the cell cycle stage specificity of methotrexate in accordance with
known tumor cell kinetics (1-5, 46, 47, 52-54, 61, 64). Oneimportant observation in
this regard is the fact that cells not actively involved in DNA synthesis; therefore,
not in the S phase ofthe cell cycle, are immune to the action ofthis drug (1-5). Ma-
lignant cells not dividing (22) or tumor cells speculated to have a biochemically al-
tered S phase (14) would thus be expected to demonstrate a decreased response to
methotrexate. Furthermore, chemotherapeutic agents interfering with cell cycle
transit; thereby preventing malignant cells from entering the S phase, would also be
expected to antagonize the activity of a subsequently administered dose of metho-
trexate (61, 63). In fact, this mechanism has recently been proposed as one possible
explanation for the antagonistic effect of prior L-asparaginase therapy upon the
activity of a subsequent dose of methotrexate (61, 64). While some investigators
have achieved an enhancement of methotrexate activity through the manipulation of
tumor cell kinetics in this manner (53, 54, 63), this approach has not yet achieved
wide clinical success. Despite this lack ofconsistent success, cell cycle consideration
will undoubtedly play an increasingly important role in the future planning ofthera-
peutic protocols with methotrexate as well as with other drugs.
As is evident, methotrexate remains a clinically important antineoplastic agent.
Fortunately, in spite of the existence of a widely recognized and accepted mode of
drug action, research concerning the biochemical activity of methotrexate has
continued. The new findings reviewed here, for instance, have provided a greater
understanding of the biochemical mechanisms underlying this drug's action. New
theories explaining empirically derived data are now possible, and these will
inevitably act to stimulate further investigations. More importantly, this continuing
examination of drug actions is revealing greater details of the nature of the ma-
lignant process. The importance of tumor cell growth parameters has thus been
recognized and is currently being exploited for an improved therapeutic effect from
cell cycle stage-specific agents as methotrexate. It should be clear, then, that in ad-
dition to the therapeutic advances from new antineoplastic agents or related
treatment modalities as immunotherapy, continued research and some new
thoughts about standard chemotherapeutic drugs such as methotrexate should
hopefully allow for theeventual successful treatment ofneoplastic diseases.
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